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Abstract
Pathway analysis has been proposed as a complement to single SNP analyses in GWAS. This study compared pathway
analysis methods using two lung cancer GWAS data sets based on four studies: one a combined data set from Central
Europe and Toronto (CETO); the other a combined data set from Germany and MD Anderson (GRMD). We searched the
literature for pathway analysis methods that were widely used, representative of other methods, and had available software
for performing analysis. We selected the programs EASE, which uses a modified Fishers Exact calculation to test for pathway
associations, GenGen (a version of Gene Set Enrichment Analysis (GSEA)), which uses a Kolmogorov-Smirnov-like running
sum statistic as the test statistic, and SLAT, which uses a p-value combination approach. We also included a modified
version of the SUMSTAT method (mSUMSTAT), which tests for association by averaging x
2 statistics from genotype
association tests. There were nearly 18000 genes available for analysis, following mapping of more than 300,000 SNPs from
each data set. These were mapped to 421 GO level 4 gene sets for pathway analysis. Among the methods designed to be
robust to biases related to gene size and pathway SNP correlation (GenGen, mSUMSTAT and SLAT), the mSUMSTAT
approach identified the most significant pathways (8 in CETO and 1 in GRMD). This included a highly plausible association
for the acetylcholine receptor activity pathway in both CETO (FDR#0.001) and GRMD (FDR=0.009), although two strong
association signals at a single gene cluster (CHRNA3-CHRNA5-CHRNB4) drive this result, complicating its interpretation. Few
other replicated associations were found using any of these methods. Difficulty in replicating associations hindered our
comparison, but results suggest mSUMSTAT has advantages over the other approaches, and may be a useful pathway
analysis tool to use alongside other methods such as the commonly used GSEA (GenGen) approach.
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Introduction
Genome wide association studies (GWAS) examine the
association of hundreds of thousands of genetic variants with
disease or other phenotypes. These studies have successfully
identified associations between genetic variants and outcome, such
as associations between SNPs at the 15q25 and 5p region and lung
cancer risk [1,2,3,4,5,6]. GWAS of lung cancer and other diseases
generally identify only a few SNPs that are associated with disease
and these usually have small effect sizes. For instance, the per allele
odds ratio for variants which implicate acetylcholine receptor
genes at 15q25 with lung cancer risk is about 1.3 [1,2,5]. SNPs
with weaker effects could be missed given the stringent require-
ments needed for adjustment for multiple comparisons.
Pathway analysis has been proposed as a complementary
approach to single SNP analyses in GWAS. Pathway analysis
groups genes that are related biologically and tests whether these
gene groups are associated with outcome. Although outcome
associated with variation at many genes may be too small to detect
in GWAS using single SNP analysis, associations may be detected
from the joint effect of many weaker signals at genes grouped into
a pathway based on shared biological function. Other benefits of
this approach are the substantial reduction of the multiple testing
burden once genes are grouped into pathways for association
testing [7] and the incorporation of biological knowledge into the
analysis, which is not accounted for in GWAS.
The number of methods developed for pathway analysis
continues to increase. Many on-line programs offer a simple gene
set enrichment approach that uses some form of Fisher’s Exact test
to determine over-representation of genes within a pathway.
Generally, a gene is assigned a P-value (usually obtained from the
SNP most strongly associated with outcome at a gene) and an
arbitrary cut-off (e.g., P#0.05) is used to separate genes strongly
associated with outcome from other genes. A Fishers Exact
calculation is then used to test for within pathway enrichment of
genes strongly associated with outcome. This approach does not
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31816account for linkage disequilibrium patterns among SNPs at
different genes in the pathway. As well, it may over-estimate the
significance of pathways with large genes (i.e., many SNPs), since
selecting the most significant SNP when there are many SNPs at a
single gene is more likely to find a strong association between gene
and outcome by chance [8,9].
The popular GSEA approach generally uses the SNP most
strongly associated with outcome at each gene to represent gene-
outcome associations. Some implementations take into account
linkage disequilibrium among SNPs and gene size bias by
performing phenotype (case-control status) permutations and
using normalization routines. Genes are first ranked by size of
their test statistic for association with outcome. A Kolmogorov-
Smirnov-like running sum statistic is then used to test for
enrichment of highly ranked genes within pathways, by comparing
the pathway test statistic to its null distribution as determined by
the phenotype permutations [9,10]. Other approaches, for
example the SUMSTAT approach which uses the sum of x
2
statistics assigned to genes as a pathway test statistic [11], can be
adapted to use phenotype permutations and normalization
methods. Alternatives to these gene set enrichment approaches,
such as methods of combining P-values (similar to meta-analyses),
have also been proposed for pathway analysis. Some of these,
incorporate methodology that accounts for potential bias related to
gene size or correlation among SNPs [12,13].
We compare four pathway analysis methods. These include a
simple gene enrichment approach in EASE, which calculates a
modified Fishers Exact probability [14], GSEA (using the GenGen
program) [9,10], a modified SUMSTAT approach, and SLAT, a P-
value combination approach [12]. The first method is representative
of early simpler approaches which use the Fishers Exact test, while
the others, as outlined above, are more sophisticated and designed to
address biases related to gene size and linkage disequilibrium among
SNPs.Wecompareandcontrasttheresultsfromanalysesusingthese
methods in two lung cancer GWAS data sets.
Materials and Methods
Samples
Data were used from case-control GWAS of lung cancer risk.
These included lung cancer cases and controls from Central
Europe [2], Toronto [2] and Germany (HGF study) [15,16] and
non-small cell lung cancer cases and controls from Texas (MD
Anderson Cancer Centre) [1]. Genotyping was performed using
either the Illumina HumanHap300 or HumanHap550 chips. Data
from the four studies were combined into two data sets: 1) Central
Europe and Toronto (CETO); and 2) Germany and Texas
(GRMD), in order to reach adequate sample size and statistical
power to detect associations in the pathway analyses. The choice
of which data sets to combine was predominantly made to ensure
similar sample sizes in the two independent analyses. Table 1
provides further details related to these studies.
Selection of pathway analysis methods
Pathway analysis methods were identified through literature
review. Methods implemented in the programs EASE [14],
GenGen (developed from GSEA) [9,10], and SLAT [12] were
chosen because they were widely used and/or representative of
other pathway analysis approaches. We chose the SUMSTAT
method based on a report indicating it had superior power to
detect pathway associations than GSEA or Fishers Exact methods
[11]. For this method an in-house SAS program was developed.
The methods are described here briefly, with details provided in
the original publications.
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With the exception of SLAT, pathway analysis methods
described here require assignment of a test statistic (or P-value)
to each gene representing its association with outcome. We used
the common practice of assigning each gene the most significant
test statistic from all SNP associations tests for the gene [8,9].
Input for EASE requires that genes significantly associated with
outcome are distinguished from all other genes, using a pre-
specified cut-off (e.g., P#0.05). Enrichment for significant genes in
each pathway is then tested using the EASE score, a modified
Fishers Exact probability representing the upper bound of
jackknife Fisher exact probabilities. Global FDRs are calculated
to account for multiple comparisons [14].
GenGen is adapted from Gene Set Enrichment Analysis
(GSEA), used originally for microarray analysis [17]. Genes are
ranked in descending order according to size of the initial
association statistic. A weighted Kolmogorov-Smirnov-like run-
ning sum statistic is then calculated that reflects over representa-
tion of higher ranked genes in a pathway in the gene list. The
weight takes on the values of SNP test statistics representing genes
in the list. A normalized enrichment statistic (NER) is calculated
for observed data, followed by phenotype permutations which give
permuted NER values, creating the null distribution from which
pathway association P-values are determined. FDRs are used to
account for multiple comparisons [9].
The modified SUMSTAT (mSUMSTAT) approach, that we
developed, is adapted from Tintle et al. [11]. The approach is
similar to that used in GenGen but the pathway test statistic is
calculated by averaging x
2 test statistics within each pathway. The
equation below shows the calculation of the normalized mean
value of the observed x
2 statistic, where S refers to a specific gene
set and p denotes the permutation. The normalized permuted
statistic is calculated the same way.
x2
n

S{mean
x2
n

S,p
 
=SD
x2
n

S,p

The p-value is determined by comparing the normalized mean
value of the x
2 statistic to the normalized permuted mean x
2
statistics [18] and a FDR is calculated according to Wang et al.
[9]. This method contrasts to that of Tintle et al., [11] through the
calculation of a normalized test statistic, and use of phenotype
permutations instead of randomly selected gene sets to determine
the null distribution.
The SLAT program calculates P-values for association of SNPs
with outcome for a defined pathway (as in this study), gene, or
region. P-values reaching a specific threshold are combined into a
test statistic. The statistic is calculated for observed and phenotype
permuted data which permits determination of a pathway P-value
[12]. No particular method for adjusting for multiple comparisons
is provided by the authors. (We used the Benjamini-Hochberg
correction to calculate FDRs for this method).
Analysis details
SNPs were excluded when the P-value for HWE in controls was
#0.001 (consistent with previous pathway analysis studies [9,11]),
the minor allele frequency was ,1%, and genotype was missing in
.5% of individuals. In addition, SNPs from the HumanHap550
chip that were used in the German GWAS were excluded if there
was no corresponding SNP from MD Anderson (the study with
which German GWAS data was combined).Subjects with sex
discrepancies (based on heterozygosity rate at chromosome X) and
those with .10% missing SNPs were excluded.
Unconditional logistic regression, using PLINK 1.05 [19]
generated allelic x
2 values for SNPs for each data set, CETO and
GRMD, for use in the programs EASE, GenGen and mSUM-
STAT. Permuted SNP association results were generated for
GenGen and mSUMSTAT using 1000 logistic regression runs with
case-control status randomly shuffled for each run. Logistic
regression analyses were adjusted for sex, age and country of origin.
The SLAT program performed its own SNP association tests for its
pathway analysis, which does not include adjustment for covariates.
SNPs were assigned to a gene if they were within 20 kb of the
gene. A SNP to gene linking file and GO level 4 pathway database
file, both obtained from the GenGen web site, were used to link
SNPs, genes and pathways. Only pathways with 15 to 200 genes
were included to avoid testing overly large or small GO pathways
[6]. The x
2 of the most significant SNP at gene was assigned to
that gene. This x
2 statistic was used to assign the cut-off value of
P#0.05 to identify strongly associated genes for analysis with
EASE. The same x
2 statistic was used in the calculation of the
pathway test statistics for GenGen and mSUMSTAT. All SNPs at
each gene were used as input for the calculation of pathway P-
values for SLAT.
The influence of gene size on pathway ranking of the four
pathway analysis methods was investigated using linear regression
analysis (SAS 9.2: SAS Institute Inc., Cary, North Carolina).
Median gene size (median number of SNPs per gene) was
calculated for each top pathway and included as the outcome
variable in a model with pathway analysis method (treated as a
categorical variable and coded into four dummy variables) as the
main effect and number of genes per pathway included as a
potential confounder.
Results
Table 2 shows the number of significant pathways identified by
the four pathway analysis methods in CETO and GRMD using a
FDR of #0.05 as the criterion to determine statistical significance.
EASE identified 10 pathways as associated with lung cancer risk in
the two data sets, 7 in CETO, 5 in GRMD, with two significant
pathways common to both data sets. The mSUMSTAT method
identified 8 pathways as significant, 8 in CETO, 1 in GRMD with
one being common to both data sets. SLAT identified five
pathways as significant, three in GRMD and two in CETO.
Since EASE identified 10 significant pathways, more than the
other methods, Table 3 shows the top 10 pathways identified in
CETO and GRMD by all pathway analysis methods (taken from
lists comprising results from both data sets). An FDR of #0.05 in
both data sets was used as the criteria for a replicated result.
Transmission of nerve impulse and the Ras guanyl nucleotide
exchange factors pathways were identified by EASE as associated
with lung cancer in CETO and GRMD (Table 3). The
Table 2. Number of significant pathway associations (using
FDR,=0.05) for Central Europe-Toronto (CETO) and
Germany-MD Anderson (GRMD) by pathway analysis method.
Data set EASE GenGen mSUMSTAT SLAT
CETO 7 0 8 2
GRMD 5 0 1 3
Both CETO and GRMD 2 0 1 0
Total 10 0 8 5
doi:10.1371/journal.pone.0031816.t002
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31816acetylcholine receptor activity pathway was identified as associated
with lung cancer in CETO and GRMD by mSUMSTAT. This
pathway contains the CHRNA3-CHRNA5-CHRNB4 gene cluster at
15q25, where GWAS have identified several SNPs associated with
lung cancer risk [1,2,5]. This pathway was the highest ranked
pathway in CETO using the GenGen method (FDR=0.19)
(Table 3). In GRMD, this pathway was ranked 16
th among all
pathways (not shown) by GenGen. The FDR was 0.43, but it was
accompanied by a nominally significant P-value (P=0.004). Other
significant pathway associations in CETO had corresponding
nominally significant P-values in GRMD, specifically: heme
metabolic process, porphyrin metabolic process, pigment biosyn-
thetic process, and 4 iron, 4 sulfur cluster binding using
mSUMSTAT; and low-density lipoprotein binding using EASE.
SLAT identified regulation of cell migration as significantly
associated with lung cancer in GRMD, with a corresponding
nominally significant P-value in CETO (Table 3).
Other than the acetylcholine receptor activity pathway, which
was identified by both mSUMSTAT and GenGen as a top
pathway, there were few top pathways identified by more than one
method. Chloride ion binding was associated with risk in CETO
according to EASE and GenGen. Complement activation-classical
pathway was associated with lung cancer risk in CETO according
to GenGen, mSUMSTAT and SLAT. Heme metabolic process
was identified as associated with risk in CETO by GenGen and
mSUMSTAT. Chromatin assembly was associated with lung
cancer risk in CETO according to mSUMSTAT and SLAT.
Interleukin-2 biosynthetic process was identified as associated with
risk by EASE and GenGen in GRMD. Regulation of cell
migration was associated with risk for GRMD according to EASE
and SLAT (Table 3). Anion transport was identified as a top
pathway by mSUMSTAT but 35 of 102 genes in this pathway
were included in the chloride ion binding pathway (64 genes),
identified as a top pathway by EASE and GenGEN (gene number
in pathways calculated following SNP mapping). Likewise, 16 of
18 genes in the interleukin 2 pathway (EASE) are included among
the 65 genes in the cytokine metabolic pathway (GenGen). Other
top pathways identified by different methods shared genes but the
overlap was 12% or less based on shared genes for the larger of the
two pathways (e.g., 20 of 50 positive regulation of phosphorous
pathway genes (GenGen) are included in the growth factor
metabolism pathway (SLAT), which has 165 genes).
The EASE method selected pathways with greater gene size
(defined using the median number of SNPs per gene) than the
other methods. The average gene size for the top EASE pathways
shown in Table 3 was 12.2 SNPs per gene, whereas average top
pathway gene size was 8.4 for GenGen, 7.4 for mSUMSTAT, and
8.7 for SLAT. Regression analysis, where pathway analysis
method was coded into four dummy variables, produced a
statistically significant association between the EASE method and
gene size (P=0.02).
As two methods identified acetylcholine receptor activity as a top
pathway we examined this association in more detail. SNPs near the
CHRNA3-CHRNA5-CHRNB4 gene cluster showing strong associa-
tions with lung cancer risk, are in strong LD, and there is overlap
among SNP teststatistics assigned to these genes (i.e., the test statistic
for the same SNP was assigned to both CHRNA5 and CHRNA3).
These pathway characteristics may bias pathway association signals
[20,21] To evaluate whether the pathway analysis was driven by a
single associated gene or the gene cluster, we examined the effect of
removing the CHRNA5 gene (where the putative causal variant is
located) and the entire gene cluster from analyses using mSUM-
STAT and GenGen. Removing CHRNA5 had no influence on
mSUMSTAT results in CETO (CHRNA5:P ,=0.001,
FDR#0.001) but FDRs fell well below the 0.05 significance level
in GRMD (CHRNA5: P=0.002, FDR=0.37). Removing CHRNA5
from the GenGen analysis resulted inreduced strength of association
in CETO (P=0.003, FDR,=0.48) but virtually no change in
GRMD (P=0.01, FDR,=0.41). However, removal of the entire
gene cluster resulted in marked reduction of the FDR and loss of
significance in the two data sets for both pathway analysis methods
(mSUMSTAT without CHRNA3-CHRNA5-CHRNB4: CETO:
P=0.19, FDR=0.56 GRMD: P=0.71, FDR=0.82; GenGen
without CHRNA3-CHRNA5-CHRNB4 CETO: P=0.11, FDR=
1.00 GRMD: P=0.32, FDR=0.76).
We further explored the association of this pathway with risk by
graphing odds ratios and 95% confidence limits for acetylcholine
receptor pathway SNPs and genes produced by unconditional
logistic regression analyses. Figure 1A shows odds ratios for
specific SNPs assigned to genes (i.e., the most significant SNP for
each gene) for the CETO analysis and for comparison, odds ratios
for these same SNPs for GRMD. In addition to SNPs in the
CHRNA3-CHRNA5-CHRNB4 gene cluster, a SNP at CHRNA2
showed a nominally significant association with risk in both data
sets (CETO: P=0.012; GRMD: P=0.022). Figure 1B shows odds
ratios for the most significant SNP assigned to each gene in either
data set (i.e., the actual SNPs used in pathway analyses in the two
data sets). Additional nominally significant associations were found
for CHRM3 (CETO: P=0.003; GRMD: P=0.028), CHRNA7
(CETO: P=0.016; GRMD: P=0.009), and CHRNA4 (CETO:
P=0.012; GRMD: P=0.038) in both data sets. In total, 6 of 8
genes associated with risk in CETO were associated with risk in
GRMD, a result greater than expected by chance given the
number of SNPs at each gene.
Discussion
Four pathway analysis methods were compared by using each to
test association of GO level 4 pathways with lung cancer risk in
two lung cancer GWAS data sets. Methods compared included
four gene set enrichment approaches, EASE, GenGen, mSUM-
STAT and a p-value combination approach, SLAT. After
adjustment for multiple comparisons using an FDR of less than
or equal to 0.05 as the criterion for a significant association, EASE
and mSUMSTAT identified more pathways associated with lung
cancer risk across the two datasets (10 and 8 respectively) than did
GenGen (no pathways), or SLAT (5 pathways). EASE and
mSUMSTAT also identified pathways that were significantly
associated with risk in both data sets: transmission of nerve impulse
and Ras guanyl nucleotide exchange factor by EASE; and the
acetylcholine receptor activity pathway by mSUMSTAT. There
was limited agreement among the different methods in the
identification of top ranked pathways. Comparing genes among
top pathways chosen by each method showed only a modest
degree of overlap.
In comparing pathway analysis methods, we examined whether
the number of SNPs per gene in pathways influenced the selection
of top pathways. The results indicated EASE, identified top
pathways with a significantly greater median number of SNPs per
gene than the other methods. This result is not unexpected. For all
gene set enrichment methods we used the common approach of
assigning the most significant SNP to represent each gene. Genes
with more SNPs, generally large genes, are more likely to be
assigned a SNP with a high association statistic, which can lead to
over estimation of significance of pathways with large genes (gene
size bias) [8,9]. We acknowledge that large genes might be more
likely to harbour multiple variants which are truly associated with
outcome, but our comments focus on statistical properties of the
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gene size bias. EASE, which uses a relatively simple approach
based on the Fishers Exact test, is susceptible to this bias.
Normalization routines and phenotype permutations incorporated
into GenGen and mSUMSTAT protect against this bias [6,22].
SLAT is also protected against this bias as it uses all SNPs in a
pathway for analysis and incorporates a phenotype shuffling
routine [12]. The more robust design of GenGen, mSUMSTAT
and SLAT provides an additional benefit, as these methods
account for correlation among SNPs within pathways.
A critical aspect of this comparison was the use of replication of
top pathways across CETO and GRMD to help evaluate the
relative performance of these methods. However, based on an
FDR of #0.05, few replicated associations were found. Lack of
study power may in part account for the small number of
replicated associations. In particular GRMD (cases=1639,
controls=1618) may have had insufficient sample size to detect
associations found in CETO (cases=2258, controls=3027).
Heterogeneity between data sets might also have contributed to
small number of replicated associations, as the German sample
was restricted to subjects under age 50, and the MD Anderson
GWAS included only ever smokers. Therefore, GRMD subjects
were younger and had a higher proportion of ever smokers
compared to CETO subjects.
Among the three methods (GenGen, mSUMSTAT and SLAT)
that are robust against gene size bias only mSUMSTAT identified
a replicated association. This was for the acetylcholine receptor
activity pathway. The association of this pathway with risk is not
unexpected as several SNPs at or near the CHRNA3-CHRNA5-
CHRNB4 gene cluster are associated with both lung cancer risk
[1,2,5] and nicotine addiction [5,23,24]. It is of interest that the
GenGen method also identified acetylcholine receptor activity as
the top ranked pathway in CETO and one of the most highly
ranked pathways in GRMD, although the result was not
significant in either data set after correcting for multiple
comparisons using the FDR. We note that the associations found
for this pathway was driven by the CHRNA3-CHRNA5-CHRNB4
gene cluster, as demonstrated by the dramatic reduction of
Figure 1. Comparison of odds ratios for acetylcholine receptor pathway showing. A) the most significant SNP for each gene used in
Central Europe-Toronto analysis and odds ratios for same SNPs for Germany MD Anderson); B) the most significant SNP assigned to each gene in
either data set (i.e., the actual SNPs used in pathway analyses in the two data sets). Chromosome number (Chr) and genes for both graphs are shown
on left. (Central Europe – Toronto SNPs: solid fill, Germany MD Anderson matching SNPs: no fill; Germany MD Anderson top SNP (differing from
Central Europe-Toronto): grey fill). A) Reference allele same in both Central Europe-Toronto and Germany-MD Anderson but chosen to show positive
association for Central Europe-Toronto. B) Reference allele always chosen to show positive association. CHRNA5 is excluded as SNPs are identical to
those representing CHRNA3. Odds ratios adjusted for age, sex and country of study.
doi:10.1371/journal.pone.0031816.g001
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mSUMSTAT and GenGen methods when data were reanalyzed
with these three genes removed from the pathway. This may
complicate the interpretation of the observed association as ideally,
significant pathways should not be identified from a signal that
might ultimately represent a single gene or variant [20,21] We
point out, however, that there are two independent risk associated
loci in this region [25] and it is currently not clear which genes in
the region are causally related to disease risk. It is preferable then
that pathways such as these are identified to be associated with
outcome by the analysis method, and the researcher can then
follow-up with additional exploratory analyses. Further investiga-
tion of this pathway did suggest that allowing the same SNP to
represent both CHRNA5 and CHRNA3 in the analysis overesti-
mated significance in the GRMD data set for mSUMSTAT and
the CETO data set for Gengen. Results from analyses that
excluded CHRNA5 are likely the most appropriate for this
pathway.
For the purpose of further comparing pathway associations
across data sets we used a less restrictive criterion for a replicated
pathway association (a significant FDR in one data set and a
nominally significant association (P,=0.05) in the second). This
permitted additional associations to be identified, although with
less confidence than those identified using the original criterion.
The mSUMSTAT method found four potential risk associated
pathways with a significant FDR in CETO and nominally
significant P-values in GRMD: heme metabolic process, porphyrin
metabolic process, pigment biosynthesis and 4 iron, 4 sulfur cluster
binding. The heme metabolic and porphyrin metabolic pathways
show a high degree of overlap. All four of these pathways include
IREB2 which is in the same region of strong LD that includes the
CHRNA3-CHRNA5-CHRNB4 cluster. SLAT identified one path-
way, regulation of cell migration, using this same criterion.
Overall, our results (along with insights from other comparisons
discussed below) suggest mSUMSTAT should be considered when
choosing a method for pathway analysis. Lack of strong replication
of pathway associations makes it difficult to evaluate GenGen and
SLAT against one another. However, the GenGen approach
appears to have some advantages. GenGen results provided some
support for an association of the acetylcholine receptor pathway
with risk, and like mSUMSTAT this method allows for the
incorporation of covariates, whereas the SLAT program does not
have this capability. Finally, GenGen is commonly used and has
provided other plausible associations in pathway analyses of
GWAS data sets [10]. On the other hand, the utility of SLAT is
difficult to assess given our results and further evaluation of this
method is needed. The rest of the discussion focuses on
mSUMSTAT and GenGen.
Our mSUMSTAT method contrasts to that of Tintle et al. [11]
through calculation of a normalized test statistic, and use of
phenotype permutations instead of randomly selected gene sets to
determine the null distribution. These changes were introduced to
address gene size bias and maintain the correlation structure
among SNPs in a pathway.
Some simulation results suggest that approaches that use the
sum or average of the x
2 as a pathway test statistic will be more
powerful than those that use the weighted Kolmogorov-Smirnov-
like running sum statistic incorporated into GenGen and related
GSEA approaches. Tintle et al. found that the original
SUMSTAT test statistic was more powerful than a GSEA
approach in a comparison where random gene sets were used to
construct the null distribution for both methods [11]. Efron and
Tibshirani found generally lower p-values using mean test statistics
when compared to GSEA in simulated gene expression analyses
[18].Their analysis used a t-test instead of a x
2 statistic, allowing
for gene expression comparisons of two groups. Permutation and
normalization approaches were the same as used here, except
normalization for GSEA also incorporated means and standard
deviations calculated from permutations with random gene sets.
Our results are consistent with these studies in that mSUMSTAT
identified several significant associations in CETO and GRMD
(with one of these replicated in both data sets), while GenGen did
not, suggesting that mSUMSTAT may have greater power to
detect associations.
Since the strongest association found by GenGen and mSUM-
STAT was for the acetylcholine receptor pathway we graphed
odds ratios and confidence limits to further explore the pathway
association. Despite weak association signals found for these
regions when the CHRNA3-CHRNA5-CHRNB4 cluster was re-
moved from analyses, the graphical presentation of results suggests
that SNPs outside of this gene cluster may contribute to the
association, as suggested by replicated associations across the two
data sets. This association appeared more convincing when
comparing the most significant SNPs representing each gene
across the two data sets (gene based comparison) as opposed to
comparing the most significant SNPs at each gene in CETO to the
same SNPs in GRMD (variant based comparison). Better evidence
for replication could result from a gene based approach versus a
SNP based approach if multiple SNPs capture the causal variant(s)
more completely than single SNPs for some pathway genes. This
can be advantageous to pathway analysis approaches which can
rely on gene based association signals to better replicate pathway
associations.
In summary, this study compared several different pathway
analysis approaches in two lung cancer GWAS data sets
comprising four studies. Difficulties in replicating associations
across studies hindered our comparison and we cannot clearly
establish one pathway analysis method as superior to the others.
However, the mSUMSTAT approach did demonstrate several
strengths such as a highly plausible association with the
acetylcholine receptor pathway and several additional suggestive
associations, while accounting for correlation among SNPs and
gene size bias. Since different pathway analysis methods can
produce different results using the same data set (as was seen here),
it is best to use more than one method when examining pathway
associations with disease risk [26]. We suggest that the mSUM-
STAT method could be used in combination with other methods,
such as the better known GenGen approach, in pathway analysis
investigations.
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